Is It Time To Review The Vaccination Strategy To Protect Adults Against Invasive Pneumococcal Disease?

Pneumococcal conjugate vaccines (PCVs) have reduced the predominant serotypes causing invasive pneumococcal disease (IPD). We assessed the impact of the paediatric 7- and 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13) among older adults. We compared serotype-specific incidence rates from...

Full description

Saved in:
Bibliographic Details
Published in:Irish medical journal 2019-03, Vol.112 (3), p.894-894
Main Authors: Corcoran, M, Mereckiene, J, Murchan, S, McElligott, M, ’Flanagan, D, Cotter, S, Cunney, R, Humphreys, H
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Cost of Illness
Female
Humans
Incidence
Ireland - epidemiology
Male
Pneumococcal Infections - epidemiology
Pneumococcal Infections - microbiology
Pneumococcal Infections - prevention & control
Pneumococcal Vaccines - administration & dosage
Serogroup
Streptococcus pneumoniae - classification
Streptococcus pneumoniae - isolation & purification
Vaccines, Conjugate - administration & dosage
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pneumococcal conjugate vaccines (PCVs) have reduced the predominant serotypes causing invasive pneumococcal disease (IPD). We assessed the impact of the paediatric 7- and 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13) among older adults. We compared serotype-specific incidence rates from 2007/08 to 2016/17, expressed as incidence rate ratios (IRR). Introducing PCV7 and PCV13 into the childhood immunisation programme resulted in a decline in these serotypes in adults ≥65 years of age, with PCV7 serotypes decreasing by 85% (IRR=0.11, 95%CI: 0.05-0.22, p
ISSN:0332-3102